多元城市人群中可待因超快代谢者的患病率
该横断面研究纳入纽约布朗克斯一家儿童医院的256例非综合征性先天性感音神经性听力损失患儿,检测CYP2D6基因的63个单核苷酸多态性和拷贝数变异,预测可待因代谢速率。结果显示9.42%为超快代谢者,白人和西班牙裔发生率较高(11.3%和11.2%)。结论强调可待因超快代谢的临床显著比例支持安全性担忧,药物基因组学个体化选择可能减少不良事件。
要点
- 儿童中可待因超快代谢者占9.42%,需警惕用药安全。
- 白人和西班牙裔儿童超快代谢发生率较高(11.3%和11.2%)。
- 药物基因组学可用于个体化选择镇痛药和剂量。
核心结论
- 可待因超快代谢者的临床显著比例强化了可待因及相关阿片类药物的安全性担忧。
- 采用药物基因组学的患者靶向方法可通过个体化选择和给药减轻不良事件。
研究设计与样本
- 横断面研究,纳入256例非综合征性先天性感音神经性听力损失患儿。
- 地点为纽约布朗克斯一家三级学术儿童医院。
- 检测CYP2D6基因的63个先前描述的单核苷酸多态性和拷贝数变异。
- 根据参与者单倍型预测CYP2D6代谢速率。
主要发现
- 研究人群中西班牙裔或拉丁裔最多,为115例(45.8%)。
- 154例(80.6%)具有对应可待因广泛代谢的单倍型。
- 18例(9.42%)被鉴定为超快代谢者,16例(8.37%)为中间代谢者。
- 仅3例(1.57%)为弱代谢者。
- 白人和西班牙裔患者超快代谢发生率较高,分别为11.3%和11.2%,亚群内变异大。
关键数值与推荐
- 超快代谢者定义为基于单倍型预测的CYP2D6代谢速率。
- 检测63个单核苷酸多态性和拷贝数变异。
- 代谢率预测基于参与者单倍型。
临床怎么用
- 临床应关注可待因超快代谢风险,尤其在白人和西班牙裔儿童中。
- 可考虑使用药物基因组学个体化选择可待因及相关阿片类药物的剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the prevalence of ultrarapid metabolizers of codeine among children in an ethnically diverse urban community. STUDY DESIGN: Cross-sectional study. SETTING: A tertiary care academic children's hospital in the Bronx, New York. SUBJECTS AND METHODS: In total, 256 children with nonsyndromic congenital sensorineural hearing loss were analyzed. DNA was assessed for 63 previously described single-nucleotide polymorphisms (SNPs) and copy number variants (CNVs) known to alter the function and expression of the CYP2D6 gene primarily responsible for codeine metabolism. The rate of CYP2D6 metabolism was predicted based on participants' haplotype. RESULTS: Ethnic distribution in the study subjects paralleled recent local census data, with the largest portion (115 children, 45.8%) identified as Hispanic or Latino. A total of 154 children (80.6%) had a haplotype that corresponds to extensive codeine metabolism, 18 children (9.42%) were identified as ultrarapid metabolizers (UMs), and 16 children (8.37%) were intermediate metabolizers. Only 3 children in our cohort (1.57%) were poor metabolizers. Patients identifying as Caucasian or Hispanic had an elevated incidence of UMs (11.3% and 11.2%, respectively) with extensive variability within subpopulations. CONCLUSIONS: The clinically significant rate of ultrarapid metabolizers reinforces safety concerns regarding the use of codeine and related opiates. A patient-targeted approach using pharmacogenomics may mitigate adverse effects by individualizing the selection and dosing of these analgesics.
引用
- Virbalas J, Morrow BE, Reynolds D, et al. The Prevalence of Ultrarapid Metabolizers of Codeine in a Diverse Urban Population. Otolaryngol Head Neck Surg. 2018. PMID: 30322340. doi:10.1177/0194599818804780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。